EUVIMEDEUVIMED entdecken
Crossref

Serum glypican-4 and visfatin in patients with newly diagnosed type 2 diabetes mellitus: associations with insulin resistance and discriminatory performance

S.M. Hasan, N.K. Zaidan

Biomeditsinskaya Khimiya · 2026-11 · 72 (5) · 362-370

DOI: 10.18097/pbmce0061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomeditsinskaya Khimiya, 2026. Verfasst von S.M. Hasan und 1 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Insulin resistance and an altered pattern of adipokine secretion are defining features of type 2 diabetes mellitus (T2DM). In this context association of two recently described adipokines, glypican-4 (GPC4) and visfatin, with insulin resistance is insufficiently characterized especially among Middle-Eastern populations. The present work assessed circulating GPC4 and visfatin, their relationship with insulin resistance, and their discriminatory performance in patients with newly diagnosed T2DM. Ninety patients with newly diagnosed T2DM (diagnosed 1–6 months earlier and receiving metformin 500 mg/day) and 60 conditionally healthy controls, all older than 40 years, took part in this case–control study. Circulating GPC4 and visfatin were quantified by ELISA and glycemic indices, HOMA-IR, the lipid profile and renal function were determined. After normality had been verified with the Shapiro–Wilk test, groups were contrasted with Student's t-test, relationships examined with Pearson's correlation, independence from age and body mass index (BMI) checked through multiple linear regression and discriminatory ability appraised by receiver operating characteristic (ROC) analysis, with areas under the curve (AUC) compared by DeLong's test. Circulating GPC4 (788.02±151.66 pg/ml vs 592.69±97.94 pg/ml) and visfatin (3.93±0.78 ng/ml vs 2.36±0.47 ng/ml) were markedly higher in the patient group than in controls (p < 0.001); patients also had a more atherogenic lipid profile, whereas renal function was comparable. Each adipokine was positively associated with HOMA-IR (GPC4: r = 0.499; visfatin: r = 0.293; p < 0.01). In multiple linear regression, group membership — rather than age or BMI — was the only independent correlate of both adipokines (standardised β = 0.584 and 0.752, respectively; p < 0.001), the models explaining 35% and 57% of the variance (R2 = 0.346 and 0.571). Visfatin and GPC4 discriminated diabetic patients from controls with AUCs of 0.950 and 0.852, respectively, the AUC of visfatin being significantly greater (p = 0.004). In patients with newly diagnosed T2DM, serum GPC4 and visfatin were already elevated at diagnosis and were associated with insulin resistance, independently of age and adiposity. However, a contribution of metformin therapy cannot be excluded. Both adipokines merit further, preferably treatment-naive, investigation as correlates of the insulin-resistant state.

Zitieren

APA

Hasan, S., & Zaidan, N. (2026). Serum glypican-4 and visfatin in patients with newly diagnosed type 2 diabetes mellitus: associations with insulin resistance and discriminatory performance. Biomeditsinskaya Khimiya, 72(5), 362-370. https://doi.org/10.18097/pbmce0061

Vancouver

Hasan S, Zaidan N. Serum glypican-4 and visfatin in patients with newly diagnosed type 2 diabetes mellitus: associations with insulin resistance and discriminatory performance. Biomeditsinskaya Khimiya. 2026;72(5):362-370. doi:10.18097/pbmce0061

BibTeX
@article{Hasan2026,
  author = {Hasan, S.M. and Zaidan, N.K.},
  title = {Serum glypican-4 and visfatin in patients with newly diagnosed type 2 diabetes mellitus: associations with insulin resistance and discriminatory performance},
  journal = {Biomeditsinskaya Khimiya},
  year = {2026},
  volume = {72},
  number = {5},
  pages = {362--370},
  doi = {10.18097/pbmce0061}
}
Kostenlos starten →